Article
Massimo Di Maio, Francesco Perrone, Pierfranco Conte
Season 2, Episode 13: Finding A Path Forward with Art Krieg
On this episode of The Pharmaverse Podcast, Art Krieg, the President of Zola Therapeutics, tells Michael that vision, endurance, resilience, and a whole lot of grit are needed to run a biotech.
Krieg has faced the rugged terrain and uphill climbs that come with building science-based companies. But just like a marathoner, he’s never stopped putting one foot in front of the other.
🎧 In this episode, Art and Michael discuss:
✅ The parallels between biotech leadership and long-distance running
✅ Lessons learned from exits, IPOs, and immuno-oncology breakthroughs
✅ Why perseverance and pacing are more important than ever in today’s market
𝐈𝐟 𝐲𝐨𝐮'𝐫𝐞 𝐚 𝐥𝐞𝐚𝐝𝐞𝐫 𝐨𝐫 𝐚𝐧 𝐚𝐬𝐩𝐢𝐫𝐢𝐧𝐠 𝐟𝐨𝐮𝐧𝐝𝐞𝐫—𝐭𝐡𝐢𝐬 𝐢𝐬 𝐚𝐧 𝐞𝐩𝐢𝐬𝐨𝐝𝐞 𝐲𝐨𝐮 𝐝𝐨𝐧’𝐭 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐦𝐢𝐬𝐬.
Related Topics
You May Also Like
Massimo Di Maio, Francesco Perrone, Pierfranco Conte
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Thakur, Sayanta & Lahiry, Sandeep
Accelerated drug approvals in oncology: Pros and cons
Article
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Article
Laleh Amiri-Kordestani & Richard Pazdur
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
Article
Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD